Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
anti-Ubiquitin+1, pAb
Product Details | |
---|---|
Synonyms | UB+1; Frameshift |
Product Type | Polyclonal Antibody |
Properties | |
Immunogen/Antigen | Synthetic peptide. |
Application |
Western Blot (1:5,000) |
Crossreactivity | Human |
Purity Detail | Protein A purified. |
Concentration | 1 mg/ml |
Formulation | Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol. |
Other Product Data |
Click here for Original Manufacturer Product Datasheet |
Declaration | Manufactured by AbFrontier |
Shipping and Handling | |
Shipping | BLUE ICE |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Use/Stability | Stable for at least 1 year after receipt when stored at -20°C. |
Documents | |
MSDS | Inquire |
Product Specification Sheet | |
Datasheet |
![]() |
Ubiquitin+1 (Ub+1) is a novel mutant form of ubiquitin that can be produced through a process known as molecular frame shift. Ub+1 can be polyubiquitinated to produce aberrant polyubiquitin chains that inhibit the 26S proteasome. Especially ub+1 is accumulated in aggregates containing amyloid-β and phosphorylated-tau. Elevated expression of Ub+1 mRNA and protein has been observed in the brains of patients with Alzheimer's disease. Also Ub+1 acts as an aggravating factor in polyglutamine-induced neurodegeneration. Protein modifier which can be covalently attached to target lysines either as a monomer or as a lysine-linked polymer. Attachment to proteins as a Lys-48-linked polymer usually leads to their degradation by proteasome. Attachment to proteins as a monomer or as an alternatively linked polymer does not lead to proteasomal degradation and may be required for numerous functions, including maintenance of chromatin structure, regulation of gene expression, stress response, ribosome biogenesis and DNA repair.
1) Van Leeuwen, F.W. et al. (1998) Science, 279, 242-247. (General)
2) Van Leeuwen, F.W. et al. (1998) Trends Neurosci. 21(8), 331-335. (General)